Silo Pharma registers resale of 1.9M shares by selling stockholders; company gets no proceeds

Filed August 6, 2026 · ~1 min read

Key Changes

• high

  This is a secondary offering: selling stockholders may resell up to 1,906,392 shares, and Silo Pharma will not receive any proceeds from those sales.

  The Offering verify on EDGAR →
• medium

  The company could receive up to $8.07 million in gross proceeds if all warrants are exercised for cash, but exercise is uncertain and at prices above the current market.

  The Offering verify on EDGAR →
• medium

  A concurrent private placement closed on July 10, 2026, providing approximately $3.5 million in net proceeds for operating expenses and working capital.

  Use of Proceeds verify on EDGAR →